<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_TAS_Taipei_Demonstrate skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><DIV id="top_title"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:TAS Taipei/Demonstrate</SPAN></H1></DIV><DIV id="HQ_page"><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><P><TITLE>Demonstrate - TAS Taipei iGEM Wiki</TITLE></P><DIV class="container" style="z-index:10;position:relative;"><DIV class="row center-block" style="text-align: left;"><NAV style="font-family:Lato;font-size:22px;background-color:#1C77C3;-webkit-transform: translateZ(0);z-index: 100;position: fixed;box-shadow: 0px 0px 10px black;"><UL style="margin-left:0px"><LI class="dropdown"><A href="https://2016.igem.org/Team:TAS_Taipei/Background"><H4 class="dropdown-toggle disabled" data-toggle="dropdown"><B>PROJECT</B></H4></A><DIV class="dropdown-menu"><DIV class="subcategories_container"><DIV><H5><A href="https://2016.igem.org/Team:TAS_Taipei/Background">Background</A></H5></DIV><DIV><H5><A href="https://2016.igem.org/Team:TAS_Taipei/Achievements">Achievements</A></H5></DIV><DIV><H5><A href="https://2016.igem.org/Team:TAS_Taipei/Collaborations">Collaborations</A></H5></DIV><DIV><H5><A href="https://2016.igem.org/Team:TAS_Taipei/Parts">Parts</A></H5></DIV></DIV><DIV style="height:140px;"><H4><B>Cataracts</B> - the leading cause of blindness. Find out how we can non-invasively <B>treat</B> and <B>prevent</B> cataract formation.</H4></DIV></DIV></LI><LI class="dropdown"><A href="https://2016.igem.org/Team:TAS_Taipei/Experimental_Summary"><H4 class="dropdown-toggle disabled" data-toggle="dropdown"><B>EXPERIMENTAL</B></H4></A><DIV class="dropdown-menu"><DIV class="subcategories_container"><DIV><H5><A href="https://2016.igem.org/Team:TAS_Taipei/Experimental_Summary#lensmodel">Lens Cataract Model</A></H5></DIV><DIV><H5><A href="https://2016.igem.org/Team:TAS_Taipei/Experimental_Summary#construct">Prevention and Treatment Constructs </A></H5></DIV><DIV><H5><A href="https://2016.igem.org/Team:TAS_Taipei/Experimental_Summary#prototype">Delivery Prototype</A></H5></DIV><DIV><H5><A href="https://2016.igem.org/Team:TAS_Taipei/Notebook">Notebook</A></H5></DIV></DIV><DIV style="height:140px;"><H4>We build <B>constructs</B> to make our great ideas become reality. Follow along our discovery of exciting science!</H4></DIV></DIV></LI><LI class="dropdown"><A href="https://2016.igem.org/Team:TAS_Taipei/Model"><H4 class="dropdown-toggle disabled" data-toggle="dropdown"><B>MODEL</B></H4></A><DIV class="dropdown-menu"><DIV class="subcategories_container"><DIV><H5><A href="https://2016.igem.org/Team:TAS_Taipei/Model#GSRFunc">GSR Function</A></H5></DIV><DIV><H5><A href="https://2016.igem.org/Team:TAS_Taipei/Model#prototype">Prototype Delivery</A></H5></DIV><DIV><H5><A href="https://2016.igem.org/Team:TAS_Taipei/Model#treatment">CH25H Treatment</A></H5></DIV><DIV><H5><A href="https://2016.igem.org/Team:TAS_Taipei/Model#software">Calculator</A></H5></DIV></DIV><DIV style="height:140px;"><H4><B>Computational Biology</B> provides us models that we cannot easily test experimentally. Click to find out the results of our modeling, and the math behind it!</H4></DIV></DIV></LI><LI class="dropdown"><A href="https://2016.igem.org/Team:TAS_Taipei/Human_Practices"><H4 class="dropdown-toggle disabled" data-toggle="dropdown"><B>HUMAN PRACTICE</B></H4></A><DIV class="dropdown-menu"><DIV class="subcategories_container"><DIV><H5><A href="https://2016.igem.org/Team:TAS_Taipei/Human_Practices#research">Research</A></H5></DIV><DIV><H5><A href="https://2016.igem.org/Team:TAS_Taipei/Human_Practices#outreach">Outreach</A></H5></DIV><DIV><H5><A href="https://2016.igem.org/Team:TAS_Taipei/Human_Practices#impact">Impact</A></H5></DIV></DIV><DIV style="height:140px;"><H4>We don't just grow cool bacteria. We make a <B>difference</B>. Find out how we tackled <B>social aspects</B> of this project.</H4></DIV></DIV></LI><LI class="dropdown"><A href="https://2016.igem.org/Team:TAS_Taipei/Safety"><H4 class="dropdown-toggle disabled" data-toggle="dropdown"><B>SAFETY</B></H4></A><DIV class="dropdown-menu"><DIV style="height:100px;"><DIV class="subcategories_container"><DIV><H5><A href="https://2016.igem.org/Team:TAS_Taipei/Safety#overview">Overview</A></H5></DIV><DIV><H5><A href="https://2016.igem.org/Team:TAS_Taipei/Safety#biosafety">Biosafety</A></H5></DIV><DIV><H5><A href="https://2016.igem.org/Team:TAS_Taipei/Safety#riskreduction">Risk Reduction Methods</A></H5></DIV><DIV><H5><A href="https://2016.igem.org/Team:TAS_Taipei/Safety#furtherquestion">Further Questions</A></H5></DIV></DIV><H4><B>Safety first.</B> Especially in a lab. Here's how we maintained and investigated the integrity and security of our work environment.</H4></DIV></DIV></LI><LI class="dropdown"><A href="https://2016.igem.org/Team:TAS_Taipei/Team"><H4 class="dropdown-toggle disabled" data-toggle="dropdown"><B>TEAM</B></H4></A><DIV class="dropdown-menu"><DIV class="subcategories_container"><DIV><H5><A href="https://2016.igem.org/Team:TAS_Taipei/Team#members">Members</A></H5></DIV><DIV><H5><A href="https://2016.igem.org/Team:TAS_Taipei/Team#about">About</A></H5></DIV><DIV><H5><A href="https://2016.igem.org/Team:TAS_Taipei/Attributions">Attributions</A></H5></DIV><DIV><H5><A href="https://2016.igem.org/Team:TAS_Taipei/Wiki_Standard_Pages">Wiki Standard Pages</A></H5></DIV></DIV><DIV style="height:140px;"><H4>Every iGEM project is the accumulation of an entire year's hard work by a group of cheerful students. <B>Meet the team!</B></H4></DIV></DIV></LI></UL></NAV></DIV><DIV class="row center-block" style="padding:10px;width:90%;background-color:#07BEB8;box-shadow:0px 0px 5px black"><DIV class="row" style="text-align:center;"><DIV class="col-sm-8" style="text-align:center;"><A href="https://2016.igem.org/Team:TAS_Taipei" style="text-decoration: none;"><H2 style="font-family:'Lato';letter-spacing:10px;color: white; font-size: 60px;  margin-top: 0;  margin-bottom: 0;"><B>
						Câ—ŽUNTERACTS</B></H2></A></DIV></DIV></DIV><DIV class="row card" id="bodycontainer" class="row"><DIV class="col-sm-2" style="padding-left:8px;"><DIV id="category_navbar"><UL class="nav nav-list" data-spy="affix" data-offset-top="160" style="-webkit-transform: translateZ(0);width:160px;margin-left:0"><LI><A href="#overview">Overview</A></LI><LI><A href="#function">Demonstrate Function</A></LI><LI><A href="#system">Demonstrate System</A></LI></UL></DIV></DIV><DIV class="col-sm-10" style="padding-right:5%"><H1>Demonstrate</H1><DIV class="row" id="overview"><P>To confirm that the protein denaturation in our cataracts fish lens model also happens to cataractous human lenses,  we designed and cloned a CRYAB construct to test the protein denaturation of human lens proteins. We ran a protein gel with the lysate of CRYAB with and without H2O2 and found that the more H2O2 added, the lighter the original CRYAB bands are and darker the higher bands become. This demonstrates that CRYAB is aggregated and clumped due to H2O2 when cataracts is formed in human lenses. Furthermore, we showed that our delivery prototype can be used to prevent and treat cataracts in our fish lens model by adding GSH and 25HC containing nanoparticles into our fish lens solution. </P><H2 id="function">Demonstrating Function using Human Proteins </H2><DIV class="row"><FIGURE class="col-sm-6"><FIGCAPTION class="darkblue"><B>Figure 2.12 </B> Our construct includes a strong promoter, strong ribosome binding site, CRYAB, his-tag, and double terminator.   </FIGCAPTION></FIGURE></DIV><DIV class="row"><DIV class="col-sm-12"><P>
                                    CRYAB is one of the main proteins in the human lens that aggregates to form cataracts. In our fish lens model, we observed protein aggregation after adding H<SUB>2</SUB>O<SUB>2</SUB>. However, we also wanted to make sure that the fish model results represent what happens with human crystallin proteins, so we designed a CRYAB construct (figure 2.12).
                                    </P><P>
                                    The final CRYAB construct contains similar components, except the first part of the open reading frame is replaced by CRYAB. CRYAB cDNA was ordered from Origene. We designed primers that were synthesized by Tri-I biotech to clone CRYAB into a Biobrick backbone, similar to how the GSR construct was made. Sequencing results (Tri-I Biotech) show that the construct was correct, and we confirmed protein expression of both CRYAB (without a poly-his tag; yellow asterisk in (figure 2.13) and CRYAB-HIS (blue asterisk in figure 2.13).
                        </P><P>
                                    To test that CRYAB aggregates in response to H<SUB>2</SUB>O<SUB>2</SUB>, we cultured bacteria expressing CRYAB and CRYAB-HIS. Liquid cultures were grown overnight and detergent was added to lyse the bacteria cultures. Different concentrations of H<SUB>2</SUB>O<SUB>2</SUB> were added to the lysates and a protein gel was prepared (figure 2.13). With increasing concentration of H<SUB>2</SUB>O<SUB>2</SUB>, the original band for CRYAB-HIS (blue asterisk) becomes lighter as higher bands (indicated by the blue bracket) increase in concentration. This shows that H<SUB>2</SUB>O<SUB>2</SUB> has the same effect on human crystallin proteins, causing them to aggregate and clump. 
                                </P></DIV></DIV><DIV class="row"><FIGURE class="col-sm-10"><FIGCAPTION class="darkblue"><B>Figure 2.13 </B> H2O2 causes human CRYAB proteins to aggregate. The expected size for CRYAB (yellow asterisk) is 20 kDa and 21 kDa for CRYAB-HIS (blue asterisk). Adding H2O2 results in a decrease of the original bands at 20 and 21 kDa, and an increase in larger proteins (blue bracket). In addition, the bands in the blue bracket also appear as a smear, which suggests that proteins may be clumping together to form various sizes.  </FIGCAPTION></FIGURE></DIV><DIV class="row"><DIV class="col-sm-12"><H2 id="system">Demonstration of Our System</H2><DIV class="row"><FIGURE class="col-sm-10"><FIGCAPTION class="darkblue"><B>Figure 3.12: Â </B>Experimental flowchart: using GSH or 25HC-packaged nanoparticles to test for prevention and treatment effects in our cataracts model.  </FIGCAPTION></FIGURE><DIV class="col-sm-12"><P>
                                    In a final experiment, we wanted to test if our delivery prototype can actually be used to prevent and treat cataracts in our model. As shown in figure 3.12, we first solubilized fish lens proteins and treated these samples with H<SUB>2</SUB>O<SUB>2</SUB> to simulate cataracts. Nanoparticles encapsulating the compounds GSH or 25HC were made. Next, we added the nanoparticles into our cataracts model to test for prevention and treatment effects. We compared the absorbance values after 48 hours. 
                                </P><P>
                                    After adding H<SUB>2</SUB>O<SUB>2</SUB> to the lens solution, absorbance values increased. However, when GSH-containing nanoparticles were also added, the absorbance values remained unchanged (figure 3.13). Similarly, when 25HC-containing nanoparticles were added, the increase in absorbance was significantly lower than with only H<SUB>2</SUB>O<SUB>2</SUB> (figure 3.14). These result show that, in our cataracts model, the compounds carried inside nanoparticles were released and effective at treating and preventing cataracts.
                                </P></DIV></DIV><DIV class="row"><FIGURE class="col-sm-6"><FIGCAPTION class="darkblue"><B>Figure 3.13: Â </B>GSH-containing nanoparticles (blue) prevented an increase in lens solution absorbance after adding H<SUB>2</SUB>O<SUB>2</SUB>. In the control group (gray), empty nanoparticles were used.   </FIGCAPTION></FIGURE><FIGURE class="col-sm-6"><FIGCAPTION class="darkblue"><B>Figure 3.14: Â </B>25HC-containing nanoparticles (pink) showed a smaller increase in lens solution absorbance after adding H<SUB>2</SUB>O<SUB>2</SUB>. In the control group (gray), empty nanoparticles were used.   </FIGCAPTION></FIGURE></DIV></DIV></DIV></DIV></DIV></DIV></DIV><DIV id="slideout"><DIV id="slidecontent"><H3>Prevention</H3><H5>GSR Eyedrop</H5><H3>Treatment</H3><H5>25HC Eyedrop</H5><H4><B> LOCS: <SPAN id="LOCS">0 Â </SPAN></B>Â Â <BUTTON type="button" class="btn btn-danger btn-md"><A href="https://2016.igem.org/Team:TAS_Taipei/Wiki_Standard_Pages#Animation">?</A></BUTTON></H4><H2 class="vertical-text" style="Lato"> Eyedrops 
    </H2></DIV></DIV><DIV id="slideoutco"><DIV id="slidecontentco"><DIV id="slidecontenttext" class="alert alert-danger"><P style="font-size:14px !important"><A href="#" class="close" data-dismiss="alert">Ã—</A><STRONG>Zoom out to see animation.</STRONG>Â Â Â Â Â <BUTTON type="button" class="btn btn-danger btn-sm"><A href="https://2016.igem.org/Team:TAS_Taipei/Wiki_Standard_Pages#Animation">?</A></BUTTON><SPAN style="font-size:14px">Your screen resolution is too low unless you zoom out </SPAN></P></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></BODY></HTML>